"We began the benefit program several months ago," said CEO David Goldberg. "It has succeeded beyond our expectations." Goldberg said APRO hopes to sign at least 25 percent of its employee client base to the programs.
The rates allow small to medium size businesses to offer benefits to employees who might otherwise lack coverage. "This is one of the further benefit services that Allegiant offers to its clients and client employees that distinguishes us from other professional employment companies," said Goldberg.
What They Do: Allegiant Professional Business Services (APRO) provides financial services and staffing to municipalities, small and medium-size businesses, relieving clients from many of the day-to-day tasks that negatively impact their core business operations, such as payroll processing, human resources support, workers' compensation insurance, safety programs, employee benefits, and other administrative and aftermarket services predominantly related to staffing -- staff leasing, temporary staffing and co-employment. APRO not only provides core services but a wide selection of employee and employer benefits and aftermarket products.
TASER International (Nasdaq: TASR) $4.31. Today announced an order from the Cleveland Division of Police in Cleveland, Ohio for an additional 400 TASER(R) X26(TM) ECDs and related accessories.
With this most recent order, the Cleveland Division of Police has purchased more than 1,400 TASER brand ECDs for its 1,600 sworn officers. Currently, more than 600 law enforcement agencies in Ohio currently deploy TASER brand ECDs. The order is expected to ship in the fourth quarter of 2009.
What They Do: TASER International's products Protect Life and Protect Truth. TASER provides advanced Electronic Control Devices (ECDs) and innovative secured digital evidence collection and management solutions for use in the law enforcement, medical, military, corrections, professional security, and personal safety markets.
ARIAD Pharmaceuticals (Nasdaq: ARIA) $2.36. Today announced the presentation of updated clinical data from its Phase 2 study evaluating oral ridaforolimus in combination with trastuzumab (Herceptin) in patients with resistant, metastatic breast cancer. As assessed by the study investigators, the clinical trial met its primary endpoint of objective response rate. The data were presented last Friday, December 11, at 5:30 p.m. C.T. at the annual San Antonio Breast Cancer Symposium in San Antonio, Texas. ARIAD is developing ridaforolimus, an investigational mTOR inhibitor, in collaboration with its partner, Merck & Co, Inc.
“The findings of this clinical study support the preclinical observation that activation of the mTOR pathway is a possible cause for resistance to trastuzumab and highlight the combination of ridaforolimus and anti-HER2 agents as potential treatment options for patients with HER2 positive, metastatic breast cancer who have progressed while on trastuzumab treatment,” stated Pierre F. Dodion, M.D., senior vice president and chief medical officer of ARIAD.
What They Do: ARIAD’s vision is to transform the lives of cancer patients with breakthrough medicines.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit http://www.smallcapreview.com/. To follow us on Twitter visit http://twitter.com/SmallCapReview. SmallCapReview has been compensated three thousand dollars by a third party LUI for its efforts with regards to Allegiant Professional.
